Chédiak-Higashi syndrome (CHS) is a multisystemic primary immunodeficiency, inherited in an autosomal recessive manner, caused by biallelic variants in the LYST gene. Alteration of lysosomal trafficking produces giant and dysfunctional granules in leukocytes, melanocytes, and nerve cells, causing recurrent infections, oculocutaneous partial albinism, hemorrhagic tendency, and risk of hemophagocytic lymphohistiocytosis.
Chédiak–Higashi syndrome
The LYST gene (Lysosomal Trafficking Regulator) encodes a protein involved in regulating the size, maturation, and movement of lysosomes and other related organelles, such as leukocyte granules, melanosomes, and platelet granules. These structures are essential for cellular degradation, immune response, pigmentation, and coagulation. In immune cells, they allow for the storage and release of enzymes and cytotoxic molecules needed to destroy microorganisms and infected cells. When pathogenic variants exist in LYST, abnormally large lysosomal granules are formed that do not mobilize or secrete properly. In neutrophils and cytotoxic lymphocytes, this defect reduces the ability to clear bacteria and favors severe or recurrent infections. In melanocytes, it alters melanin distribution and causes hypopigmentation of skin, hair, and eyes. Neuronal involvement can produce progressive neurological manifestations, especially in atypical forms or in long-term survivors. Inheritance is autosomal recessive, meaning the affected person must inherit two altered copies of the gene. It is an ultra-rare disease, with fewer than 500 cases described in the literature and no clear ethnic predilection.
Symptoms
The onset of Chédiak-Higashi syndrome usually occurs in childhood. The main symptoms include recurrent and severe bacterial infections, partial oculocutaneous albinism (light or silvery hair, pale skin, photophobia or nystagmus), and a tendency to bleed or bruise easily. A characteristic complication is the accelerated phase, equivalent to hemophagocytic lymphohistiocytosis, which presents with fever, hepatosplenomegaly, cytopenias, and potentially fatal systemic inflammation. Peripheral neuropathy, ataxia, cognitive impairment, or parkinsonism may also appear. The finding of giant granules in leukocytes on a peripheral blood smear is a key morphological clue for diagnosis.
Disease management
The management of CHS is complex and should be performed in centers with experience in immunodeficiencies and hemophagocytic lymphohistiocytosis. Infections require early treatment and, in some cases, antimicrobial prophylaxis or granulocyte colony-stimulating factor support. The accelerated phase is treated with immunosuppression and chemotherapy to control inflammatory hyperactivation. Hematopoietic stem cell transplantation, ideally performed early and before significant neurological damage, is the only curative treatment for hematological and immunological manifestations. However, it does not correct albinism nor necessarily prevent progressive neurodegeneration, thus requiring long-term neurological, ophthalmological, and supportive follow-up.
Genes analyzed
Bibliography
Talbert ML, Malicdan MCV, Introne WJ. Chediak-Higashi syndrome. Curr Opin Hematol. 2023 Jul 1;30(4):144-151.
Deng R, Zhao J, Liang J, et al. Chediak-Higashi Syndrome: a Comprehensive Case Report and Literature Review. Clin Lab. 2025 Apr 1;71(4).
Greene S, Soldatos A, Toro C, et al. Chedíak-Higashi Syndrome: Hair-to-toe spectrum. Semin Pediatr Neurol. 2024 Dec;52:101168.
